Trial Profile
A Single-Arm Study to Assess the Safety of Transplantation With Umbilical Cord Blood Augmented With Human Placental-Derived Stem Cells From Partially Matched Related Donors in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Mar 2014
Price :
$35
*
At a glance
- Drugs PSC 100 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 27 Mar 2014 New trial record